Mochida Pharmaceutical Co., Ltd. (JP:4534)
:4534
Want to see JP:4534 full AI Analyst Report?
4534 Stock Chart & Stats
¥3615.00
-¥40.00(-1.17%)
At close: 4:00 PM EST
¥3615.00
-¥40.00(-1.17%)
Day’s Range― - ―
52-Week Range¥2,859.00 - ¥3,965.00
Previous CloseN/A
Volume18.00K
Average Volume (3M)34.37K
Market Cap
¥116.72B
Enterprise Value¥89.68B
Total Cash (Recent Filing)¥54.69B
Total Debt (Recent Filing)¥830.00M
Price to Earnings (P/E)12.6
Beta0.65
Next Earnings
May 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.34%
Share Statistics
EPS (TTM)70.12
Shares Outstanding36,390,000
10 Day Avg. Volume38,620
30 Day Avg. Volume34,366
Financial Highlights & Ratios
PEG Ratio0.75
Price to Book (P/B)0.86
Price to Sales (P/S)1.07
P/FCF Ratio15.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)208.3
Revenue Forecast (FY)¥110.00B
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetMochida’s very low debt-to-equity and robust equity ratio provide durable financial flexibility. This reduces refinancing and solvency risk, enabling steady funding for R&D, commercial efforts or opportunistic M&A and supporting resilience through industry cycles over the next months.
Sustained Profitability / MarginsHealthy gross and net margins indicate durable cost control and pricing power within its specialty franchises. Strong margins support consistent cash generation, allowing continued reinvestment, dividend capacity or targeted pipeline spend even if top-line growth remains subdued.
Specialty Focus And In-licensing ModelConcentration in specialty therapeutic areas plus MR-driven promotion and an in-licensing/commercialization model creates a defensible niche. This reduces late‑stage R&D burden, leverages existing distribution, and can steady product cadence and revenues over the medium term.
Bears Say
Declining Revenue GrowthA sustained decline and a recent significant revenue drop constrain scale and limit internal funding for R&D and commercialization. If top-line weakness persists, it can erode market share, reduce pricing leverage, and force reliance on cost cuts or external partnerships to sustain growth.
Volatile Free Cash FlowVolatile free cash flow creates uncertainty in financing operations, dividends and pipeline investments. Even with strong FCF-to-net-income, past negative FCF growth can force timing mismatches for capital allocation, increasing reliance on cash reserves or external options when funding needs peak.
Concentration In Japan / Market Concentration RiskHeavy dependence on the domestic Japanese market concentrates revenue and regulatory/reimbursement exposure. This limits geographic diversification, making growth sensitive to local policy, pricing pressures and demographic trends, which can restrain medium‑term upside and increase country-specific risk.
Mochida Pharmaceutical Co., Ltd. News
4534 FAQ
What was Mochida Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Mochida Pharmaceutical Co., Ltd. lowest stock price was ¥2859.00 and its highest was ¥3965.00 in the past 12 months.
What is Mochida Pharmaceutical Co., Ltd.’s market cap?
Mochida Pharmaceutical Co., Ltd.’s market cap is ¥116.72B.
When is Mochida Pharmaceutical Co., Ltd.’s upcoming earnings report date?
Mochida Pharmaceutical Co., Ltd.’s upcoming earnings report date is May 15, 2026 which is in 21 days.
How were Mochida Pharmaceutical Co., Ltd.’s earnings last quarter?
Mochida Pharmaceutical Co., Ltd. released its earnings results on Feb 06, 2026. The company reported ¥70.12 earnings per share for the quarter, beating the consensus estimate of N/A by ¥70.12.
Is Mochida Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Mochida Pharmaceutical Co., Ltd.’s price is currently Overvalued.
Does Mochida Pharmaceutical Co., Ltd. pay dividends?
Mochida Pharmaceutical Co., Ltd. pays a Semiannually dividend of ¥40 which represents an annual dividend yield of 2.34%. See more information on Mochida Pharmaceutical Co., Ltd. dividends here
What is Mochida Pharmaceutical Co., Ltd.’s EPS estimate?
Mochida Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mochida Pharmaceutical Co., Ltd. have?
Mochida Pharmaceutical Co., Ltd. has 36,390,000 shares outstanding.
What happened to Mochida Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Mochida Pharmaceutical Co., Ltd. reported an EPS of ¥70.12 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.537%.
Which hedge fund is a major shareholder of Mochida Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4534
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mochida Pharmaceutical Co., Ltd.
Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan. The company provides cardiovascular, analgesic, gastrointestinal, neurological, anti-infective, antidiabetics, and anticancer products, as well as hormone and biological preparations, and biosimilars; diagnostic reagents, such as reagents for fertility/infertility and other reagents; and face and body care, hair care, and skincare products, as well as dermatology, psychiatry, obstetrics, and gynecology products. It also developing drugs for the treatment of intractable diseases. The company has collaboration agreements with Amarin Corporation plc for the development and commercialization of ethyl icosapentate products; and Gene Techno Science Co., Ltd. to develop new regenerative medicine for the treatment of digestive rare and intractable diseases, such as congenital isolated hypoganglionosis. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.
Technical Analysis
Kaken Pharmaceutical Co
―
Kissei Pharmaceutical Co
―
Towa Pharmaceutical Co
―
KYORIN Pharmaceutical Co.,Ltd.
―
SAWAI GROUP HOLDINGS Co., Ltd.
―
Options Prices
Currently, No data available
---